Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 143-148

  Nakajima, Sei Ichiro ^a,b   Niizeki, Hiroto ^a,b   Tada, Mitsuo ^a   Nakagawa, Koji ^c   Kondo, Satoshi ^b   Okada, Futoshi ^d   Kobayashi, Masanobu ^a,e  

^a Institute for Genetic Medicine   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

^e HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Apoptosis; Breast cancer; P53; Trichostatin A

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; PROTEIN BAX; PROTEIN P21; PROTEIN P53; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENE THERAPY; GENETIC VECTORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68249138788     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000417     Document Type: Article

References (37)

1. Bartek J, Bartkova J, Vojtesek B, et al: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703, 1991.
2. Chen PL, Chen YM, Bookstein R and Lee WH: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580, 1991.
3. Tonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991.
4. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985-991, 1996.
5. Kock H, Harris MP, Anderson SC, et al: Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 67: 808-815, 1996.
6. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ and Roth JA: Adenoviral mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1665-1671, 1996.
7. Yang B, Stambrook PJ and Markowitz SD: Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649-1657, 1996.
8. Pirollo KF, Hao Z, Rait A, et al: P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 14: 1735-1746, 1997.
9. Ogawa N, Fujiwara T, Kagawa S, et al: Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 73: 367-370, 1997.
10. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y and Koizumi K: A new antifungal antibiotic, trichostatin. J Antibiot 29: 1-6, 1976.
11. Yoshida M and Beppu T: Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A. Exp Cell Res 177: 122-131, 1988.
12. McBain JA, Eastman A, Nobel CS and Mueller GC: Apoptotic death in adenocarcinoma cell lines by butyrate and other histone deacetylase inhibitors. BioChem Pharmacol 53: 1357-1368, 1997.
13. Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707, 1997.
14. Struhl K: Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12: 599-606, 1998.
15. Sambucetti LC, Fischer DD, Zabludoff S, et al: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947, 1999.
16. Takimoto R, Kato J, Terui T, et al: Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor. Cancer Biol Ther 4: 421-428, 2005.
17. Katayose D, Wersto R, Cowan KH and Seth P: Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Differ 6: 1207-1212, 1995.
18. Macho A, Decaudin D, Castedo M, Hirsch T, Susin SA and Zamzami N: Chloromethyl-X-Rosamine is an aldehyde-fixable potential sensitive fluorochrome for the detection of early apoptosis. Cytometry 25: 333-340, 1996.
19. Choi S, Kobayashi M, Wang J, et al: Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with adriamycin. Clin Exp Metastasis 18: 45-50, 2000.
20. Kimura Y, Furuhata T, Shiratuchi T, Nishimori H, Hirata K and Nakamura Y: GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene 15: 1369-1374, 1997.
21. Oda K, Arakawa H, Tanaka T, et al: p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862, 2000.
22. Kostic C and Shaw PH: Isolation of sixteen novel p53 response genes. Oncogene 19: 3978-3987, 2000.
23. Attardi LD, Reczek EE, Cosmas C, et al: PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 14: 704-718, 2000.
24. Wang J, Kobayashi M, Sakurada K, Imamura M, Moriuchi T and Hosokawa M: Possible roles of adult T-cell leukemia-derived factor/thioredoxin I the drug resistance of ATL to Adriamycin. Blood 89: 2480-2487, 1997.
25. Sabbatini P, Lin J, Levine AJ and White E: Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev 9: 2184-2192, 1995.
26. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
27. Wu GS, Burns TF, McDonald ER III, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143, 1997.
28. Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B: A model for p53-induced apoptosis. Nature 389: 300-305, 1997.
29. Caelles C, Helmberg A and Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994.
30. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M: Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183, 1995.
31. Rowan S, Ludwig RL, Haupt Y, et al: Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15: 827-838, 1996.
32. Ding HF, Lin YL, McGill G, et al: Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem 275: 38905-38911, 2000.
33. El-Deiry WS: Regulation of p53 downstream genes. Semin Cancer Biol 8: 345-357, 1998.
34. Marchenko ND, Zaika A and Moll UM: Death signal-induced localization of p53 protein to mitochondria. J Biol Chem 275: 16202-16212, 2000.
35. Moll UM and Zaika A: Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 493: 65-69, 2001.
36. Wolff S, Erster S, Palacios G and Moll UM: p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res 18: 733-744, 2008.
37. Terui T, Murakami K, Takimoto R, et al: Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63: 8948-8954, 2003.